Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122161853 | 12216185 | 3 | F | 20160905 | 20160329 | 20160907 | EXP | JP-ROCHE-1730160 | ROCHE | , INUI N, FUJISAWA T, ENOMOTO N, NAKAMURA Y, KUROISHI S, YOKOMURA K, KOSHIMIZU N, SATO M, TOYOSHIMA M, SHIRAI T, MASUDA M, YAMADA T, IMOKAWA S AND SUDA T. MAINTENANCE THERAPY WITH PEMETREXED AND BEVACIZUMAB VERSUS PEMETREXED MONOTHERAPY IN NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (ABSTRACT E20504).. JOURNAL OF CLINICAL ONCOLOGY 2016 MAY;34 (S15):-. | 0.00 | Y | 0.00000 | 20160908 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122161853 | 12216185 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | ON DAY 1 OF A 21 DAY CYCLE FOR 4 CYCLES | U | 125085 | 15 | MG/KG | |||||||
| 122161853 | 12216185 | 2 | SS | PEMETREXED | PEMETREXED | 1 | Intravenous (not otherwise specified) | FOR INDUCATION THERAPY | U | 0 | 500 | MG/M**2 | |||||||
| 122161853 | 12216185 | 3 | SS | PEMETREXED | PEMETREXED | 1 | Intravenous (not otherwise specified) | FOR MAINTENANCE THERAPY | U | 0 | 500 | MG/M**2 | |||||||
| 122161853 | 12216185 | 4 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | AN AREA UNDER THE CURVE = 6 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122161853 | 12216185 | 1 | Non-small cell lung cancer |
| 122161853 | 12216185 | 2 | Non-small cell lung cancer |
| 122161853 | 12216185 | 4 | Non-small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122161853 | 12216185 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122161853 | 12216185 | Alanine aminotransferase increased | |
| 122161853 | 12216185 | Anaemia | |
| 122161853 | 12216185 | Aspartate aminotransferase increased | |
| 122161853 | 12216185 | Cardiac arrest | |
| 122161853 | 12216185 | Constipation | |
| 122161853 | 12216185 | Fatigue | |
| 122161853 | 12216185 | Febrile neutropenia | |
| 122161853 | 12216185 | Gastrointestinal haemorrhage | |
| 122161853 | 12216185 | Gastrointestinal perforation | |
| 122161853 | 12216185 | Hypertension | |
| 122161853 | 12216185 | Leukopenia | |
| 122161853 | 12216185 | Nausea | |
| 122161853 | 12216185 | Neutropenia | |
| 122161853 | 12216185 | Pneumonitis | |
| 122161853 | 12216185 | Proteinuria | |
| 122161853 | 12216185 | Stomatitis | |
| 122161853 | 12216185 | Thrombocytopenia | |
| 122161853 | 12216185 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |